Literature DB >> 16741709

CD4+CD25+ T regulatory cells induced by LPS-activated bone marrow dendritic cells suppress experimental autoimmune uveoretinitis in vivo.

Kirsten Siepmann1, Sabine Biester, Jarmila Plsková, Elizabeth Muckersie, Linda Duncan, John V Forrester.   

Abstract

BACKGROUND: Tolerance-inducing DC are considered to be less mature than immunogenic DC, but the conditions promoting a less mature DC phenotype are not clear. We have previously shown that lipopolysaccharide (LPS) can have differential effects on DC function depending on the timing of DC exposure to LPS. Here, we show that early LPS-activated bone marrow derived DC (early DC, eDC), when administered subcutaneously to mice in vivo, promote tolerance to EAU induced via immunisation with interphotoreceptor retinol binding protein (IRBP) peptide 161-180. The effect correlates with the failure of eDC to secrete IL-12, and appears to be mediated in part via expansion of naturally occurring CD4+ CD25+ T regulatory cells (Tregs), which also mediate suppression of EAU on adoptive transfer to naive mice followed by immunization with autoantigen.
METHODS: Immature DC were prepared from BMDC cultures. Early DC (eDC) and late DC (lDC) for tolerance experiments were obtained by differential timing of LPS addition and their cytokine secretion profile was analyzed. eDC and lDC were subcutaneously injected into mice. From the dLN CD4+ CD25+ GITR+ T regulatory cells found to express FoxP3 were isolated and transferred into mice prior to immunisation with IRBP. The immune response was scored by histopathology. Tregs were characterized in vitro by intracellular staining, cytokine secretion assay and transwell experiments.
RESULTS: eDC secrete IL-10 but no IL-12 or IFNgamma. When injected subcutaneously into naive mice, they expand the population of CD4+ CD25(+high) GITR+ T cells expressing FoxP3 in the dLN, thus increasing the total number of IL-10 producing cells. eDC induced Tregs inhibit CD4+ CD25- T effector cell proliferation by a contact dependent process, and both eDC and Tregs suppress retinal damage when adoptively transferred.
CONCLUSIONS: We suggest that DC maturation may be necessary for both tolerance and immunity, but differential levels of activation and/or cytokine production direct the outcome of DC-T cell interaction and this is determined by IL-12 production. T regulatory cells induced in vivo by contact with eDC are able to suppress disease in the EAU model by adoptive transfer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 16741709     DOI: 10.1007/s00417-006-0356-9

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  39 in total

Review 1.  Immunopathogenic mechanisms in intraocular inflammation.

Authors:  J V Forrester; P G McMenamin
Journal:  Chem Immunol       Date:  1999

2.  Role of IL-6 in directing the initial immune response to schistosome eggs.

Authors:  A C La Flamme; A S MacDonald; E J Pearce
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

3.  Differential regulatory capacity of CD25+ T regulatory cells and preactivated CD25+ T regulatory cells on development, functional activation, and proliferation of Th2 cells.

Authors:  Michael Stassen; Helmut Jonuleit; Christian Müller; Matthias Klein; Christoph Richter; Tobias Bopp; Steffen Schmitt; Edgar Schmitt
Journal:  J Immunol       Date:  2004-07-01       Impact factor: 5.422

4.  Secretion of interleukin-10 or interleukin-12 by LPS-activated dendritic cells is critically dependent on time of stimulus relative to initiation of purified DC culture.

Authors:  Hui-Rong Jiang; Elizabeth Muckersie; Marie Robertson; Heping Xu; Janet Liversidge; John V Forrester
Journal:  J Leukoc Biol       Date:  2002-11       Impact factor: 4.962

5.  Regulation of T cell-dependent and -independent IL-12 production by the three Th2-type cytokines IL-10, IL-6, and IL-4.

Authors:  H Takenaka; S Maruo; N Yamamoto; M Wysocka; S Ono; M Kobayashi; H Yagita; K Okumura; T Hamaoka; G Trinchieri; H Fujiwara
Journal:  J Leukoc Biol       Date:  1997-01       Impact factor: 4.962

6.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

Review 7.  IL-3 in dendritic cell development and function: a comparison with GM-CSF and IL-4.

Authors:  Manfred B Lutz
Journal:  Immunobiology       Date:  2004       Impact factor: 3.144

8.  Immune regulatory activity of CD34+ progenitor cells: evidence for a deletion-based mechanism mediated by TNF-alpha.

Authors:  Hilit Gur; Rita Krauthgamer; Esther Bachar-Lustig; Helena Katchman; Rinat Arbel-Goren; Alain Berrebi; Tirza Klein; Arnon Nagler; Antonio Tabilio; Massimo F Martelli; Yair Reisner
Journal:  Blood       Date:  2004-10-07       Impact factor: 22.113

9.  The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors.

Authors:  Tiffany Horng; Gregory M Barton; Richard A Flavell; Ruslan Medzhitov
Journal:  Nature       Date:  2002-11-21       Impact factor: 49.962

10.  Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity.

Authors:  Mauritius Menges; Susanne Rössner; Constanze Voigtländer; Heike Schindler; Nicole A Kukutsch; Christian Bogdan; Klaus Erb; Gerold Schuler; Manfred B Lutz
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

View more
  14 in total

Review 1.  Ocular diseases: immunological and molecular mechanisms.

Authors:  Jing Song; Yi-Fei Huang; Wen-Jing Zhang; Xiao-Fei Chen; Yu-Mian Guo
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

2.  Vaccination with collagen-pulsed dendritic cells prevents the onset and reduces the disease severity in the mouse model of spontaneous polychondritis.

Authors:  M Sidhu; M M Griffiths; D S Bradley
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

3.  CD40-activated B cells are more potent than immature dendritic cells to induce and expand CD4(+) regulatory T cells.

Authors:  Jian Zheng; Yinping Liu; Yu-Lung Lau; Wenwei Tu
Journal:  Cell Mol Immunol       Date:  2010-01       Impact factor: 11.530

4.  Ocular regulatory T cells distinguish monophasic from recurrent autoimmune uveitis.

Authors:  Yan Ke; Guomin Jiang; Deming Sun; Henry J Kaplan; Hui Shao
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-05-16       Impact factor: 4.799

5.  CD4+Foxp3+ T-regulatory cells in noninfectious uveitis.

Authors:  Steven Yeh; Zhuqing Li; Farzin Forooghian; Frank S Hwang; Matthew A Cunningham; Seth Pantanelli; Julie C Lew; Keith K Wroblewski; Susan Vitale; Robert B Nussenblatt
Journal:  Arch Ophthalmol       Date:  2009-04

Review 6.  Immunopathogenic Background of Pars Planitis.

Authors:  Joanna Przeździecka-Dołyk; Agnieszka Węgrzyn; Anna Turno-Kręcicka; Marta Misiuk-Hojło
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2015-10-05       Impact factor: 4.291

7.  Jagged-1 is required for the expansion of CD4+ CD25+ FoxP3+ regulatory T cells and tolerogenic dendritic cells by murine mesenchymal stromal cells.

Authors:  Emer F Cahill; Laura M Tobin; Fiona Carty; Bernard P Mahon; Karen English
Journal:  Stem Cell Res Ther       Date:  2015-03-11       Impact factor: 6.832

8.  Lipopolysaccharide-primed heterotolerant dendritic cells suppress experimental autoimmune uveoretinitis by multiple mechanisms.

Authors:  Izabela P Klaska; Elizabeth Muckersie; Cristina Martin-Granados; Maria Christofi; John V Forrester
Journal:  Immunology       Date:  2016-12-18       Impact factor: 7.397

Review 9.  Immune Privilege and Eye-Derived T-Regulatory Cells.

Authors:  Hiroshi Keino; Shintaro Horie; Sunao Sugita
Journal:  J Immunol Res       Date:  2018-05-20       Impact factor: 4.818

10.  Ginsenoside Rp1 Exerts Anti-inflammatory Effects via Activation of Dendritic Cells and Regulatory T Cells.

Authors:  Jingyu Bae; Jihye Koo; Soochan Kim; Tae-Yoon Park; Mi-Yeon Kim
Journal:  J Ginseng Res       Date:  2012-10       Impact factor: 6.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.